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b-catenin negatively regulates expression of the prostaglandin
transporter PGT in the normal intestinal epithelium and colorectal
tumour cells: a role in the chemopreventive efficacy of aspirin?
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BACKGROUND: Levels of the pro-tumorigenic prostaglandin PGE2 are increased in colorectal cancer, previously attributed to increased
synthesis through COX-2 upregulation and, more recently, to decreased catabolism. The functionally linked genes 15-prostaglandin
dehydrogenase (15-PGDH) and the prostaglandin transporter PGT co-operate in prostaglandin degradation and are downregulated in
colorectal cancer. We previously reported repression of 15-PGDH expression by the Wnt/b-catenin pathway, commonly
deregulated during early colorectal neoplasia. Here we asked whether b-catenin also regulates PGT expression.
METHODS: The effect of b-catenin deletion in vivo was addressed by PGT immunostaining of b-catenin /lox-villin-cre-ERT2 mouse
tissue. The effect of siRNA-mediated b-catenin knockdown and dnTCF4 induction in vitro was addressed by semi-quantitative and
quantitative real-time RT-PCR and immunoblotting.
RESULTS: This study shows for the first time that deletion of b-catenin in murine intestinal epithelium in vivo upregulates PGT protein,
especially in the crypt epithelium. Furthermore, b-catenin knockdown in vitro increases PGT expression in both colorectal adenoma-
and carcinoma-derived cell lines, as does dnTCF4 induction in LS174T cells.
CONCLUSIONS: These data suggest that b-catenin employs a two-pronged approach to inhibiting prostaglandin turnover during
colorectal neoplasia by repressing PGT expression in addition to 15-PGDH. Furthermore, our data highlight a potential mechanism
that may contribute to the non-selective NSAID aspirin’s chemopreventive efficacy.
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Recent studies in the Lancet (Algra and Rothwell, 2012; Rothwell
et al, 2012a, b) have reinforced interest in the potential value of
using NSAIDs, such as aspirin, in colorectal cancer chemopreven-
tion. Over much of the last few decades, a major focus of colorectal
cancer chemoprevention has been inhibition of COX-2, an
inducible cyclooxygenase isoform that is upregulated at the
medium/large adenoma stage, and to which the elevated levels of
the protumorigenic prostaglandin PGE2 have previously been
attributed (Rigas et al, 1993; Eberhart et al, 1994; Elder et al, 2002).
However, several lines of evidence suggest a potential role for
COX-1 in colorectal neoplasia. For example, tumorigenesis in
animal models can be suppressed by deletion of either COX-1 or
COX-2 genes (Chulada et al, 2000), or by administration of a COX-
1-selective inhibitor (Kitamura et al, 2002), though the precise role
of COX-1 in intestinal neoplasia is unclear. Our recent paper in
Gut (Smartt et al, 2012) highlighted a mechanism by which COX-1
could contribute to early colorectal cancer development. We
showed that b-catenin, activated at the earliest stages of colorectal
neoplasia, can repress expression of the colorectal tumour
suppressor and prostaglandin catabolising enzyme 15-prostaglan-
din dehydrogenase (15-PGDH). Here, we now show that b-catenin
also represses expression of a second gene crucial for prostaglan-
din catabolism, the prostaglandin transporter PGT. PGT (aka
SLCO2A1) mediates uptake of secreted prostaglandins, enabling
their oxidative inactivation by cytoplasmic 15-PGDH (Nomura
et al, 2004). Like 15-PGDH, downregulation of PGT has been
reported in both human colorectal tumours and in pre-malignant
adenomas in APCmin/þ mice, and this was suggested to result, at
least in part, from epigenetic silencing (Holla et al, 2008).
However, we hypothesised that b-catenin may also have a role in
repression of PGT expression in colorectal cancer, as we reported
previously for 15-PGDH. Here we show that modulating b-catenin
expression or function increases PGT expression, both in the
intestinal epithelium in vivo, and in colorectal adenoma and
carcinoma cells in vitro. Our data suggest that b-catenin
co-ordinately regulates prostaglandin turnover through the
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negative regulation of both PGT and 15-PGDH expression, and
highlight a potential mechanism that could contribute to the
chemopreventive efficacy of the non-selective NSAID aspirin.
MATERIALS AND METHODS
The colon carcinoma-derived cell lines HCT15, HCT116, HT29,
LOVO, LS174T, SW480 and SW620, obtained from the American
Type Culture Collection (Rockville, MD, USA); the HCA7 colony
29 (HCA7) colon carcinoma cell line, a kind gift of Susan Kirkland
(Kirkland, 1985); the dox-inducible dnTCF4-expressing LS174T/
dnTCF4 cell line, a kind gift from Hans Clevers (van de Wetering
et al, 2002); and colon adenoma-derived cell lines PC/AA/C1, PC/
AA/C1/SB10C, PC/BH/C1, S/AN/C1 and S/RG/C2 derived in this
laboratory (Paraskeva et al, 1984, 1989; Williams et al, 1990) were
maintained as described previously (Paraskeva et al, 1984; Moore
et al, 2009), except for PC/AA/C1 and PC/AA/C1/SB10C, which
were maintained on conditioned medium (Williams et al, 1990).
Immunohistochemical staining using a rabbit polyclonal PGT
antibody (kind gift of Michel Fortier, Quebec, Canada) and
inducible intestinal b-catenin ablation in mice were carried out
and validated as previously described (Smartt et al, 2012), as was
intestinal epithelial cell fractionation (see also Mariadason et al,
2005). RNA interference, immunoblotting and mRNA preparation
were also performed as previously described (Smartt et al, 2012).
Semi-quantitative RT-PCR was carried out as in Chell et al (2006),
with minor modifications, and quantitative real-time RT-
PCR was carried out as described previously (Moore et al, 2009),
using PGT primers from Qiagen (Crawley, West Sussex, UK).
RESULTS
Preliminary studies suggested that, similar to 15-PGDH, PGT also
shows an expression gradient in the human intestinal epithelium,
being highest in the differentiated luminal/villus compartment
(Figure 1A). A similar PGT expression gradient was also observed
in the murine small intestinal epithelium, both at the mRNA
(Figure 1B) and protein level (Figure 1C). As Wnt/b-catenin
transcriptional activity is known to be highest in the proliferative
crypt compartment (van de Wetering et al, 2002; Kosinski et al,
2007), we hypothesised that PGT may also be repressed by
b-catenin in intestinal epithelial cells. Importantly, the gradient of
PGT expression was lost following inducible b-catenin ablation
(Figure 1D; Fevr et al, 2007). Elevated PGT expression was
particularly noticeable in crypt epithelia (compare Figure 1F with E),
where b-catenin activity is normally highest (Batlle et al, 2002; van
de Wetering et al, 2002). This increase is consistent with previously
published microarray analysis (1.67-fold increase, Fevr et al, 2007),
confirming that b-catenin represses PGT expression in the normal
murine intestinal epithelium.
We then hypothesised that b-catenin may also repress PGT
expression in human colorectal cancer cells, as is the case for
15-PGDH. Indeed, in line with this hypothesis, basal PGT levels are
reportedly very low to undetectable in most colorectal carcinoma
cell lines (Holla et al, 2008). We confirmed and extended this
observation to include cell lines derived from sporadic (S/RG/C2,
S/AN/C1) and familial adenomatous polyposis patient (PC/AA/C1,
PC/BH/C1) adenomas and one in-vitro-transformed adenoma cell
line (PC/AA/C1/SB10C) (Figure 2A). Indeed, in our hands, PGT
mRNA was only readily detectable in LoVo carcinoma-derived and
PC/BH/C1 adenoma-derived cells under basal conditions. Notably,
siRNA-mediated knockdown of b-catenin increased PGT mRNA
expression in both adenoma- and carcinoma-derived cell lines
(Figure 2B and C). In addition, PGT mRNA levels were consistently
increased in the colorectal carcinoma cell line LS174T/dnTCF4,
48 h following induction of dnTCF4, a dominant-negative form of
this b-catenin-binding partner that is unable to bind b-catenin
(Figure 2D and E). Hence, taken together, these data suggest that
b-catenin represses PGT expression in both the normal intestinal
epithelium and in colorectal cancer.
DISCUSSION
In this article, we have identified a novel link between two
important pathways in colorectal neoplasia, Wnt/b-catenin and
PGE2 signalling, through the negative regulation of PGT expres-
sion. Therefore, similar to 15-PGDH, PGT expression could be
widely downregulated at a very early stage of colorectal neoplasia
in sporadic tumours as well as those arising in the context of a
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Figure 1 (A, B) Gradient of PGT protein and mRNA expression with
differentiation along the crypt–villus axis in intestinal epithelium. (A) PGT
immunohistochemistry shows high PGT expression in the differentiated
human villus epithelium. Scale bar represents 50mm. (B) Differential
fractionation of the murine intestinal epithelium followed by microarray
gene expression analysis (Mariadason et al, 2005) shows that, like the
differentiation marker villin, PGT mRNA expression increases along the
crypt–villus axis. In contrast, expression of the proliferation marker PCNA
and the Wnt/b-catenin target c-Myc both decrease along the crypt–villus
axis. Data represents expression relative to fraction 10 in fractions 10, 8, 6,
4, 2 and 1. This gradient of PGT expression is confirmed at the protein level
by immunohistochemistry (see C). (C–F) Inducible b-catenin ablation
increases crypt epithelial PGT expression levels. Deletion of b-catenin was
induced in b-catenin /lox-villin-creERT2 mice by tamoxifen injection (D, F);
injected b-cateninþ /lox-villin-creERT2 mice (C, E) were used as a control.
PGT staining shows PGT expression throughout the crypt–villus axis in the
absence of b-catenin (D), particularly evident in crypt and lower villus
epithelium (F as compared with E) (representative examples from 96 h
post induction). Scale bars represent 50 mm.
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germline APC mutation. Downregulation of PGT, in addition
to 15-PGDH, may constitute a very effective means of
increasing local PGE2 levels as impaired PGT-mediated prosta-
glandin import would be expected to directly increase extracellular
prostaglandin concentrations available to interact with cell surface
receptors.
The ability of b-catenin to downregulate both 15-PGDH and PGT,
two crucial regulators of prostaglandin catabolism, points towards
the importance of elevated COX-1-derived prostaglandin levels
during early colorectal neoplasia before COX-2 upregulation, and
may go some way to explain the particular efficacy in colorectal
cancer chemoprevention of the non-selective NSAID aspirin.
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Figure 2 (A) PGT mRNA expression screen in colorectal adenoma- and carcinoma-derived cell lines. PC/AA/C1, S/AN/C1, PC/BH/C1 and S/RG/C2 are
adenoma-derived cell lines, PC/AA/C1/SB10C is an in-vitro-transformed adenoma-derived cell line and the remainder are carcinoma-derived. Semi-
quantitative real-time PCR analysis confirmed that most colorectal carcinoma-derived cell lines express low levels of PGT with the exception of LoVo.
Interestingly, a similar pattern was seen in our adenoma-derived cell lines, with mostly very low expression with the exception of PC/BH/C1 cells (NTC¼ no
template control, RT¼ no reverse transcriptase enzyme control). (B, C) b-catenin siRNA knockdown increases PGT expression. (B) Immunoblotting
(IB) demonstrating that transient b-catenin siRNA transfection effectively reduced b-catenin protein levels in S/RG/C2, SW480 and LoVo cell lines (48 h).
Semi-quantitative PCR analysis (PCR) revealed a marked and consistent increase in PGT mRNA levels in S/RG/C2, SW480 and LoVo cells following b-
catenin siRNA-mediated knockdown (48 h). (C) Quantitative real-time PCR analysis confirms the increase in PGT mRNA apparent in B. (D) Induction of
dnTCF4 increases PGT expression immunoblotting demonstrates effective induction in LS174T/dnTCF4 cells of dnTCF4 with 1mgml 1 doxycycline (dox;
48 h). Semi-quantitative PCR analysis (PCR) demonstrates a consistent increase in PGT mRNA levels in LS174T/dnTCF4 cells following dox-mediated
induction of dnTCF4 (48 h). (E) Quantitative real-time PCR analysis confirms the increase in PGT mRNA apparent in D. Results shown are representative of
a minimum of three independent repeat experiments. a-tubulin and b-actin serve as loading controls.
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